Clinical Trials Logo
  1. Home
  2. Lung Cancer
  3. NCT05799027
  4. Details
NCT05799027 Clinical Trial

Raman Spectroscopic Analysis of Bronchoscopic Biopsy for Diagnosing Lung Cancer

Lung Cancer Clinical Trial

Official title:
Raman Spectroscopic Analysis of Bronchoscopic Biopsy for Diagnosing Lung Cancer

Clinical Trial Details — Status: Not yet recruiting

Administrative data
NCT number NCT05799027
Other study ID # 2022-NHLHCRF-LX-01-0201-05
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date March 31, 2023
Est. completion date December 31, 2024

Study information
Verified date March 2023
Source China-Japan Friendship Hospital
Contact Mingming Deng, MD
Phone 86 18801336854
Email isdeng1017@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical trial is to evaluate raman spectroscopic analysis of bronchoscopic biopsy for diagnosing lung cancer in visible lesions in the airway. The main question it aims to answer are: the diagnostic efficacy raman spectroscopic analysis of bronchoscopic biopsy for diagnosing lung cancer. The bronchoscopic biopsy sample of patients with visible lesions in the airway would undergo raman spectrum analysis.

Recruitment information / eligibility
Status Not yet recruiting
Enrollment 200
Est. completion date December 31, 2024
Est. primary completion date December 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 90 Years
Eligibility Inclusion Criteria: - Patients who plan to undergo bronchoscopic biopsy or EBUS-TBNA - Visible intratracheal lesions under bronchoscope - Non-visible lesions suspected of lung cancer Exclusion Criteria: - The patient could not tolerate further examination aimed at clarifying the cause of the disease or refused to accept further examination aimed at clarifying the cause of the disease due to poor general condition, serious organ dysfunction, etc - The patient has no definite diagnosis

Study Design

Related Conditions & MeSH terms

Intervention

Diagnostic Test:
• Raman spectrum
The bronchoscopic biopsy sample of patients with visible lesions in the airway would undergo raman spectrum analysis.

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
China-Japan Friendship Hospital

Outcome
Type Measure Description Time frame Safety issue
Primary To establish the sensitivities and specificities of Raman spectroscopic analysis of bronchoscopic biopsy for lung cancer. The diagnosis would be confirmed according to the pathological results. 7 days after the biopsy
See also
  Status Clinical Trial Phase
Completed NCT03918538 - A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors N/A
Recruiting NCT05078918 - Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors N/A
Active, not recruiting NCT04548830 - Safety of Lung Cryobiopsy in People With Cancer Phase 2
Completed NCT04633850 - Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05583916 - Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery N/A
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Not yet recruiting NCT06376253 - A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers Phase 1
Recruiting NCT05898594 - Lung Cancer Screening in High-risk Black Women N/A
Active, not recruiting NCT05060432 - Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT03575793 - A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer Phase 1/Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Terminated NCT01624090 - Mithramycin for Lung, Esophagus, and Other Chest Cancers Phase 2
Terminated NCT03275688 - NanoSpectrometer Biomarker Discovery and Confirmation Study
Not yet recruiting NCT04931420 - Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels Phase 2
Recruiting NCT06010862 - Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors Phase 1
Recruiting NCT06052449 - Assessing Social Determinants of Health to Increase Cancer Screening N/A
Not yet recruiting NCT06017271 - Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
Recruiting NCT05787522 - Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk